Member Profile

Medigen Vaccine Biologics Corporation (MVC) is a biopharmaceutical company focusing on the development and production of vaccines and biologics. We have PIC/S GMP certified cell culture commercial mass production capabilities, and target global and regional infectious diseases to develop novel vaccines and biosimilar drugs via international alliances. We are based in Taiwan and human health is our priority. Since MVC was established, we are dedicated to developing countermeasures for the prevention and treatment of emerging infectious diseases such as COVID-19, Enterovirus A71, Dengue, and Influenza vaccines. We established Taiwan’s first cell-based vaccines and biologics manufacturing facility with PIC/S GMP certificate which is located in Hsinchu Biomedical Science Park. The vaccine facility is equipped with biosafety level 2+ production line, R&D lab, aseptic fill-finish line, QC and QA systems, enabling us to meet the demands of the domestic and regional markets. Our mission is to provide innovative medical products and technologies, aiming to become a leader in the field of vaccines and biologics, ensuring the protection of all individuals from the threat of numerous diseases and contributing to Taiwan’s and global epidemic prevention efforts.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2016 MVC inaugurated Taiwan’s first cell-based vaccine manufacturing plant in Hsinchu Biomedical Science Park.
   2020 MVC Dengue vaccine which licensed from US NIH was completed the phase 2 POC clinical trial.
   2021 MVC received the Emergency Use Authorization (EUA) of MVC COVID-19 Vaccine in Taiwan.
   2021 MVC COVID-19 Vaccine was selected as the WHO solidarity trial vaccine, and conducted the global phase 3 clinical trial.
   2022 MVC received the Emergency Use Authorization (EUA) of MVC COVID-19 Vaccine in Paraguay.
   2023 MVC received the drug license of MVC FLU Quardrivalent pre-filled syringe injection in Taiwan.
   2023 MVC received the drug license of MVC EV71 Vaccine (Envacgen) in Taiwan.
   2023 MVC file the New Drug Application of MVC EV71 Vaccine (Envacgen) to Drug Administration of Vietnam (DAV).